

WHO operational handbook on tuberculosis

Module 3: Diagnosis

Rapid diagnostics for
tuberculosis detection

2021 update



World Health
Organization

WHO operational handbook on tuberculosis

Module 3: Diagnosis

**Rapid diagnostics for
tuberculosis detection**

2021 update

WHO operational handbook on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis detection, 2021 update

ISBN 978-92-4-003058-9 (electronic version)

ISBN 978-92-4-003059-6 (print version)

© **World Health Organization 2021**

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. WHO operational handbook on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis detection, 2021 update. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Design by Inis Communication.

Contents

Acknowledgements	v
Abbreviations and acronyms	vi
1. Introduction	1
1.1 Background	1
1.2 About this guide	3
1.3 Target audience	3
2. Diagnostic tests with WHO recommendations	5
2.1 Conventional diagnostic tests for the diagnosis of TB	7
2.2 Initial tests for diagnosis of TB with drug-resistance detection	7
2.3 Initial tests for diagnosis of TB without drug-resistance detection	12
2.4 Follow-on diagnostic tests for detection of additional drug resistance	14
2.5 Tests WHO recommends against using	17
2.6 Phenotypic and genotypic DST	18
3. Implementing a new diagnostic test	23
3.1 Placement of diagnostic tests in the tiered laboratory network	23
3.2 Pretest probability and test accuracy considerations	27
3.3 Epidemiologic considerations	32
3.4 Multi-disease platform considerations	32
3.5 Steps and processes for implementing a new diagnostic test	33

4. Model algorithms	47
4.1 Algorithm 1 – mWRD as the initial diagnostic test for TB	51
4.2 Algorithm 2 – LF-LAM testing to aid in the diagnosis of TB among PLHIV	73
4.3 Algorithm 3 – DST for second-line drugs for RR-TB or MDR-TB patients	90
4.4 Algorithm 4 – mWRD as the initial or follow-onv test to detect Hr-TB	99
4.5 Illustrative algorithm combinations	109
5. Suggested reading	115
6. References	119
Annex 1: Budgetary considerations for implementing a new diagnostic test	125
Annex 2: Information sheets on the newly recommended products	128
A2.1 Information sheet: Practical considerations for implementation of the Abbott RealTime MTB and Abbott RealTime MTB RIF/INH tests	129
A2.2 Information sheet: Practical considerations for implementation of the BD MAX MDR-TB test	135
A2.3 Information sheet: Practical considerations for implementation of the Roche cobas MTB and cobas MTB-RIF/INH assays	140
A2.4 Information sheet: Practical considerations for implementation of the Bruker-Hain Lifesciences FluoroType MTB and FluoroType MTBDR	145
A2.5 Information sheet: Practical considerations for implementation of the Cepheid Xpert MTB/XDR test	151
A2.6 Information sheet: Practical considerations for implementation of the Nipro Genoscholar PZA-TB II assay	156

Acknowledgements

The update of this operational handbook was led by Nazir Ahmed Ismail, Carl-Michael Nathanson, Lice González-Angulo and Alexei Korobitsyn, with support from Cecily Miller and Matteo Zignol, and under the overall direction of Tereza Kasaeva, Director of the World Health Organization (WHO) Global TB Programme (WHO/GTB). The WHO/GTB gratefully acknowledges the support of the following experts who have contributed to the review of the document: David Branigan, Treatment Action Group, United States of America (USA); Kathleen England, independent consultant, USA; Fernanda Dockhorn Costa, National Tuberculosis Programme, Brazil; Patricia Hall, Centers for Disease Control and Prevention, USA; Rumina Hasan, Department of Pathology and Microbiology, Aga Khan University, Pakistan; Brian Kaiser, Global Drug Facility, Stop TB Partnership, Switzerland; Farzana Ismail, National Institute for Communicable Diseases Supranational TB Reference Laboratory, South Africa; Mark Nicol, University of Western Australia, Australia; Thomas Shinnick, independent consultant, USA; Elisa Tagliani, San Raffaele Supranational TB Reference Laboratory, Italy; and Wayne Van Gemert, TB Diagnostics Market Strategies, Stop TB Partnership, Switzerland. In addition, we thank the Global Laboratory Initiative, a Working Group of the Stop TB Partnership, and members of the Core Group not already mentioned above for the development of the information sheets on the diagnostic technologies included in the Handbook, in particular, special thanks to Sarabjit Singh Chadha, FIND, India; Christopher Gilpin, International Organization for Migration, Switzerland; and Abiola Tubi, National TB and Leprosy Control Programme, Nigeria.

Christopher Dobosz designed all figures.

This product was developed with support from the United States Agency for International Development (USAID) and the Russian Federation.

Abbreviations and acronyms

AFB	acid-fast bacilli
AHD	advanced HIV disease
AIDS	acquired immunodeficiency syndrome
ART	antiretroviral therapy
CC	critical concentration
CI	confidence interval
CSF	cerebrospinal fluid
DNA	deoxyribonucleic acid
DR-TB	drug-resistant tuberculosis
DST	drug-susceptibility testing
EQA	external quality assessment
FIND	Foundation for Innovative New Diagnostics
FL-LPA	line-probe assay for first-line drugs
GDG	Guideline Development Group
GLI	Global Laboratory Initiative
GTB	Global TB Programme
HIV	human immunodeficiency virus
Hr-TB	isoniazid-resistant, rifampicin-susceptible TB
IT	information technology
LAM	lipoarabinomannan
LAMP	loop-mediated isothermal amplification
LF-LAM	lateral flow lipoarabinomannan assay
LoD	limit of detection
LPA	line-probe assay

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_23736

